Notice on Convening the 2024 Annual General Meeting
Filed with SSE · · 6 pages · Chinese
CABIO Biotech (Wuhan) Co. Ltd. on 6ix
Earlier from CABIO Biotech (Wuhan)
- Announcement on Adjusting 2024 Annual Profit Distribution Plan
- Announcement on Attending 2024 SSE STAR Market Biological Products and CXO Industry Collective Performance Briefing
- Announcement on Changing Enterprise Type
- Announcement on Self-Inspection Report on Purchase and Sale of Shares by Relevant Subjects Related to This Transaction
- Indicative Announcement on Risk of Purchase of Assets and Raising of Supporting Funds through Shares Issuance and Cash Payment and Related Transaction
Later from CABIO Biotech (Wuhan)
- Announcement on Changing Major Asset Restructuring Project and Audit Signatory Accountant for 2025
- Announcement on Resolution of the 2024 Annual General Meeting
- Announcement on Convening the Q1 2025 Performance Briefing
- Announcement on Reply to the Review Inquiry Letter of Application for Purchasing Assets and Raising Supporting Funds by Issuing Shares and Paying Cash as well as Related Party Transactions
- Announcement on Adjusting the Upper Limit of Phase II Share Repurchase Price after Implementation of Dividend Distribution for 2024
Follow CABIO Biotech (Wuhan) into a list and get an email when it puts out news.
Follow CABIO Biotech (Wuhan)